

INTEGRA LIFESCIENCES HOLDINGS CORP  
Form SD  
May 31, 2018

**United States**

**Securities and Exchange Commission**

**Washington, D.C. 20549**

**Form SD**

**Specialized Disclosure Report**

**INTEGRA LIFESCIENCES HOLDINGS CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation or organization)**

**0-26224**  
**Commission**

**51-0317849**  
**(I.R.S. Employer**

**File Number**  
**311 ENTERPRISE DRIVE**

**Identification No.)**

**PLAINSBORO, NEW JERSEY 08536**

**(Address of principal executive offices)**

**Glenn G. Coleman**

**Corporate Vice President and Chief Financial Officer**

**(609) 275-0500**

**(Name and telephone number, including area code, of the person to contact in connection with this report)**

The rule pursuant to which this form is being filed, and the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017

**Section 1 Conflict Minerals Disclosure**

Item 1.01 and 1.02 Conflict Minerals Disclosure and Exhibit

Integra LifeSciences Holdings Corporation ( Integra, the Company , we , us or our ) is unable, at this time, to determine whether any of the tin, tantalum, tungsten or gold (the Conflict Minerals ) used in its products may have originated in the Democratic Republic of the Congo or adjoining countries. Some of our suppliers have identified that products they provide to us may include recycled Conflict Minerals.

A Conflict Minerals Report is provided as an Exhibit to this Report under Section 2.01 below, and is available at the following internet website <https://www.integralife.com/ConflictMineralsPolicy>.

The Conflict Minerals Report is not required to be audited.

**Section 2 Exhibits**

**Item 2.01 Exhibits**

**Exhibit 1.01 Conflict Minerals Report**

A Conflict Minerals Report is attached.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

INTEGRA LIFESCIENCES HOLDINGS  
CORPORATION

By: /s/ Glenn G. Coleman  
Glenn G. Coleman

May 31, 2018

Chief Financial Officer and Corporate  
Vice President, International